About Horizon Therapeutics Plc

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

At the moment the company generates 1518M USD in revenues.

On its last earning announcement, the company reported a profit of 2.62$ per share.

The book value per share is 5.16$

Horizon Therapeutics Plc website

Create a solid portfolio with HZNP

Add HZNP to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
1518M 73.40% 125M 8.19% 517M 2.62 - - 212M 5.16 316M -131M 185M